Cargando…
Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy
Background: To characterize humoral response after standard anti-SARS-CoV-2 vaccination in Rituximab-treated patients and to determine the optimal time point after last Rituximab treatment for appropriate immunization. Methods: Sixty-four patients who received Rituximab within the last seven years p...
Autores principales: | Töllner, Maximilian, Speer, Claudius, Benning, Louise, Bartenschlager, Marie, Nusshag, Christian, Morath, Christian, Zeier, Martin, Süsal, Caner, Schnitzler, Paul, Schmitt, Wilhelm, Bergner, Raoul, Bartenschlager, Ralf, Lorenz, Hanns-Martin, Schaier, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952324/ https://www.ncbi.nlm.nih.gov/pubmed/35330069 http://dx.doi.org/10.3390/jcm11061739 |
Ejemplares similares
-
Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers
por: Benning, Louise, et al.
Publicado: (2022) -
Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients
por: Benning, Louise, et al.
Publicado: (2022) -
Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2
por: Speer, Claudius, et al.
Publicado: (2021) -
Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients
por: Benning, Louise, et al.
Publicado: (2022) -
Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients
por: Benning, Louise, et al.
Publicado: (2022)